This is a delivery order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The $234,478 contract is for the Gene Therapy Resource Program (GTRP) Pharmacology and Toxicology Core Laboratory. It is a cost-plus-fixed-fee contract with a period of performance through June 30, 2024. Lovelace Biomedical Research Institute...
This is a federal contract award to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization, by the National Heart Lung and Blood Institute (NHLBI). The $1,609,194.07 contract is a Delivery Order under the Gene Therapy Resource Program (GTRP) to provide pharmacology/toxicology core laboratory services for a scientific project. This work supports the National Institutes of Health's research efforts in gene therapy. The contract does not have a set-aside...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The $625,343.90 contract is for the PHARMACOLOGY/TOXICOLOGY CORE LABORATORY PROJECT under the Gene Therapy Resource Program (GTRP). Lovelace will provide a range of preclinical research services to support the...
This federal contract award was issued by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to the Lovelace Biomedical Research Institute. The $1,143,792.16 cost-plus-fixed-fee contract is for the GENE THERAPY RESOURCE PROGRAM (GTRP) and calls for the awardee to provide a Pharmacology and Toxicology Core Laboratory. The contract does not have a set-aside designation. Lovelace Biomedical Research Institute is a not-for-profit...
This is a cost-plus-fixed-fee task order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Heart Lung and Blood Institute to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $352,485.43 task order is for pharmacology/toxicology core laboratory services in support of the Gene Therapy Research Program (GTRP). It does not have a set-aside designation. Lovelace Biomedical has a history of serving as a...
This federal contract award was issued by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The $203,807.96 contract is a delivery order for Task Area A under the Pharmacology-Toxicology Core Lab task order 7 of the NHLBI's Gene Therapy Resource Program (GTRP). The work, which has no set-aside designation,...
This is a federal contract award issued by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The $1,013,722.26 award is for Task Order 6, Task Area B under the GTRP Pharmacology-Toxicology Core Lab contract. The work will be performed in Albuquerque, NM and the period of performance runs through April 15,...
This is a federal contract award from the National Heart Lung and Blood Institute (NHLBI), a civilian agency under the Department of Health and Human Services, to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI) for the "Gene Therapy Resource Program (GTRP), Pharmacology-Toxicology Core Lab." The contract is a $1,748,740.00 cost-plus-fixed-fee delivery order with a period of performance through July 31, 2017. LBERI, a non-profit organization doing business as...
<p>The Lovelace Biomedical Research Institute has been awarded a $3,720,750.00 delivery order contract from the National Institutes of Health National Center for Advancing Translational Sciences to conduct efficacy and safety evaluations of lead gene therapy candidates in neuromuscular junction disease mouse models and develop bioanalytical assay methods. The cost plus fixed fee contract will be performed in Albuquerque, New Mexico over a three year period ending September 2026.</p>
This is a $385,704.00 cost-plus-fixed-fee delivery order contract awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to the Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The contract is for the characterization of spontaneous osteogenesis, or bone formation, after surgical segmental bone defect in a large animal model. The work will take place in...